31 recruiting, 8 not yet recruiting, 5 terminated, 4 active not recruiting. 52 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 52 | Recruiting 31, Not yet recruiting 8, Terminated 5, Active not recruiting 4, Completed 4 |
| Phase 2 | 12 | Recruiting 8, Active not recruiting 3, Not yet recruiting 1 |
Follow BeOne Medicines: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0920 - Diffuse Large B-Cell Lymphoma, B-cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-12-11 | 2026-10-21 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors BON-106 - Solid Tumor, Advanced Solid Tumor | Phase 1 | Not yet recruiting | BeOne Medicines | 96 | 2026-12-01 | 2026-10-26 |
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0050 - Diffuse Large B-Cell Lymphoma, B-Cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-11-30 | 2026-10-19 |
| A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors BG-92505, Anti-Cancer Agent - Advanced Solid Tumor | Phase 1 | Not yet recruiting | BeOne Medicines | 137 | 2026-11-30 | 2026-10-27 |
| A Study of BON-C1393 in Adults With Advanced Solid Tumors BON-C1393, Bevacizumab, Capecitabine - Solid Tumors, Advanced Solid Tumors | Phase 1 | Not yet recruiting | BeOne Medicines | 90 | 2026-11-23 | 2026-10-29 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic Impairment Sonrotoclax - Hepatic Impairment, Healthy Adult Participants | Phase 1 | Not yet recruiting | BeOne Medicines | 12 | 2026-11-01 | 2026-10-20 |
| A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic Impairment Tacabrutideg - Hepatic Impairment, Healthy Adult Participants | Phase 1 | Not yet recruiting | BeOne Medicines | 24 | 2026-10-22 | 2026-10-02 |
| A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395 BGB-43395, Midazolam, Celecoxib - Healthy Adult Participants | Phase 1 | Recruiting | BeOne Medicines | 24 | 2026-09-25 | 2026-10-23 |
| A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations BG-85738, Tislelizumab, Cetuximab - RAS Mutation, Advanced Solid Tumor | Phase 1 | Recruiting | BeOne Medicines | 100 | 2026-09-02 | 2026-10-23 |
| A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food on the Pharmacokinetics of BGB-58067 in Healthy Participants BGB-58067 Tablet (F-01 Formulation), BGB-58067 Tablet (F-02 Formulation) - Healthy Volunteers | Phase 1 | Recruiting | BeOne Medicines | 32 | 2026-07-21 | 2026-09-28 |
| An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies BG-75202, Hypomethylation Agent (HMA) - Myeloid Malignancy | Phase 1 | Recruiting | BeOne Medicines | 118 | 2026-06-23 | 2026-09-28 |
| A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer ELI-002 7P, Tislelizumab, mFOLFIRINOX - Pancreatic Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2026-06-22 | 2026-10-28 |
| A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults Sonrotoclax Tablet for Oral Suspension, Sonrotoclax Tablet - Healthy Volunteers | Phase 1 | Completed | BeOne Medicines | 12 | 2026-06-17 | 2026-10-23 |
| A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors HH160 - Solid Tumor, Non-small Cell Lung Cancer | Phase 1 | Recruiting | Huahui Health | 299 | 2026-06-11 | 2026-08-21 |
| A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants BGB-58067, Phenytoin, Itraconazole - Healthy Volunteers | Phase 1 | Recruiting | BeOne Medicines | 30 | 2026-06-04 | 2026-10-09 |
| A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors BG-C0979, Tislelizumab - Advanced Solid Tumor | Phase 1 | Recruiting | BeOne Medicines | 84 | 2026-04-13 | 2026-09-28 |
| A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases BG-A3004, Placebo - Skin Diseases | Phase 1 | Recruiting | BeOne Medicines | 98 | 2026-03-19 | 2026-08-10 |
| A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors BG-75098, BGB-43395, Fulvestrant - Advanced Solid Tumor | Phase 1 | Recruiting | BeOne Medicines | 105 | 2025-12-11 | 2026-09-28 |
| An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist - Breast Cancer, Advanced Solid Tumor | Phase 1 | Recruiting | BeOne Medicines | 86 | 2025-12-11 | 2026-09-28 |
Showing 20 of 52. Sign in to see all of them.
Lymphoma, Mantle-Cell (5) · Breast Neoplasms (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Large B-Cell, Diffuse (4) · Neoplasm Metastasis (4) · Recurrence (4) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3) · Lymphoma, Non-Hodgkin (3) · Burkitt Lymphoma (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Leukemia, Myeloid, Acute (2) · Neoplasm, Residual (2) · Neoplasms (2)
tislelizumab (10) · zanubrutinib (5) · Fulvestrant (4) · Bevacizumab (3) · Drug Therapy (3) · Azacitidine (2) · Cetuximab (2) · Dexamethasone (2) · Letrozole (2) · blinatumomab (2) · obinutuzumab (2) · AMG 757 (1) · Antineoplastic Agents (1) · Aromatase Inhibitors (1) · Capecitabine (1)
China (34) · Australia (33) · United States (32) · New Zealand (13) · South Korea (12) · Spain (11) · Brazil (10) · Italy (10) · France (9) · Germany (8) · Japan (8) · United Kingdom (6) · Turkey (Türkiye) (4) · Belgium (3) · Canada (3)
Alvaro Alencar, MD (1) · Kevin Soares, MD (1)
2025 (6), 2023 (4)